S.Korea’s CDMO giant Samsung Biologics to offer CRO services
Samsung Biologics Co., the world’s largest contract drugmaker, will enter the contract research organization (CRO) market by leveraging its va...
Samsung Biologics to spin off biosimilar unit Samsung Bioepis
Samsung Biologics Co., the world’s largest contract drugmaker, will undergo a strategic split to separate its contract development and manufac...
Lotte Biologics eyes first ADC CDMO order in 2025
SAN FRANCISCO -- Lotte Biologics Co., the drug consignment development and production unit of South Korean conglomerate Lotte Group, will seek to wi...
Celltrion BioSolutions launched to venture into CDMO
Celltrion Inc. on Tuesday launched its contract development and manufacturing organization unit Celltrion BioSolutions Co. in its foray into the CDM...
Boryung, Lotus Pharma signs CDMO deal on anticancer injection
South Korea's Boryung Corp. said on Thursday it signed a contract with Lotus Pharmaceutical, a Taiwanese oncology firm, for contract development and...
SK Pharmteco bags obesity treatment deal worth up to $1.4 bn
SK Pharmteco Co., a contract development and manufacturing organization (CDMO), has secured an obesity treatment order worth up to 2 trillion won ($...
Celltrion to break ground on CDMO plant in 2025: Chairman Seo
South Korea’s leading biosimilar developer Celltrion Inc. will break ground on its first contract development and manufacturing organization (...
Samsung Biologics wins $668 million CDMO deal with European pharma
Samsung Biologics Co., the world’s largest contract drugmaker, said on Wednesday it has signed two drug manufacturing contracts worth a combin...
Celltrion to establish CDMO subsidiary
Celltrion Inc., South Korea’s largest biosimilar maker, said on Friday it plans to establish a contract development and manufacturing organiza...
Celltrion earmarks billions of dollars to build CDMO plant: chairman
Celltrion Inc., South Korea’s largest biosimilar maker, will spend several billion dollars to build a factory to crack the contract developmen...
Celltrion chairman announces venture into CDMO market
South Korea’s biosimilar maker Celltrion Inc. will venture into the contract development and manufacturing organization (CDMO) market, the com...
Lotte to restructure bio business to focus on CDMO
South Korea’s retail-to-chemical conglomerate Lotte Group will restructure its bio business to focus on the profit-making medicine bio develop...
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
SK Inc., the holding and investment company of SK Group, South Korea’s second-largest conglomerate, is negotiating to sell a major asset of it...
Samsung Biologics eyes windfall gain amid US-China row
SAN DIEGO – Samsung Biologics Co. is enjoying a stream of contract development and manufacturing order inquiries from big pharmaceutical compa...
S.Korea’s GC Cell targets global cell therapy CDMO business
GC Cell Corp., an affiliate of South Korea’s major pharmaceutical company GC Biopharma Corp., is targeting the cell therapy contract developme...
SK Pharmteco launches new viral vector platforms, key for CGT
SK Pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), has recently introduced two...
South Korean bio, pharma industry set to take leap
South Korea’s chemical maker LG Chem Ltd. is expected to reap more than 1 trillion won ($768.5 million) in sales this year from its new growth...
Lotte Biologics to break ground on 1st local CDMO plant in 2024
South Korea’s Lotte Biologics Co. is set to start building its first local facility for drug manufacturing next year, aiming for 400,000 liter...
Prestige Biologics partners with Indian company for CDMO
Prestige Biologics Co., a South Korean biopharmaceutical contract development and manufacturing organization (CDMO) company, is expanding its CDMO b...
IMM PE invites potential buyers for Genuone worth $752 mn
South Korea’s top-tier contract drugmaker Genuone Sciences Inc. with an estimated value of up to 1 trillion won ($752 million) is smooth saili...
SK Pharmteco gears up for big leap in advanced biotherapies
SK Pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), is upping the ante in its b...
SK Bioscience buys 6.5 million Novavax shares for $83.4 million
SK Bioscience Co., the drug-making unit of South Korea’s SK Group, said on Wednesday it has signed a deal to buy 6.5 million shares in US vacc...
SK Pharmteco secures 12 global pharma clients, sets up US R&D center
SK Pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), has secured 12 global pharm...
Samsung Biologics, Pfizer sign $411.3 mn agreement for long-term CDMO
Samsung Biologics Co., the world’s No. 1 contract drugmaker, announced a groundbreaking strategic partnership with Pfizer on Thursday, marking...
Samsung Biologics to double production by 2032; eyes ADCs, M&As
BOSTON – Samsung Biologics Co., the world’s No. 1 contract drugmaker, plans to more than double its total annual production capacity to ...
BIO USA 2023 to draw S.Korean biotech leaders, startups
More than 500 South Korean companies from top business groups to AI-based biotech startups are slated to attend the Bio International Convention 202...
SK Pharmteco again seeks $382 mn in pre-IPO funding
SK Pharmteco Co., a contract development and manufacturing organization (CDMO), is eyeing pre-initial public offering funding again after it dropped...
Samsung Biologics to invest $1.5 bn for 5th CDMO factory
Samsung Biologics Co. is slated to inject 2 trillion won ($1.5 billion) to build its fifth plant in South Korea. It will be a fast follow-up investm...
S.Korea's Prestige Biologics attracts $59 mn overseas investment
Prestige Biologics Co., a South Korean biopharmaceutical contract development and manufacturing organization (CDMO) company, announced on Tuesday th...
Daewoong accelerates investment in CDMO business
Daewoong, the holding company of South Korea's pharmaceutical-oriented Daewoong Group, is speeding up its pace to beef up its contract development a...
